This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
Dr. Auerbach reports (227:326, 1974) on the topical use of dibutylated cyclic adenosine monophosphate (cyclic AMP) in patients with psoriasis, the rationale being to elevate the reduced levels of skin cyclic AMP in these people. He observed either no improvement or worsening of lesions and suggests several possible reasons for lack of improvement. I should like to add two more. First, the reduced levels may represent a homeostatic control on a substance to which the skin of the psoriatic is unduly sensitive and which might in fact cause the lesions. As an occasional sufferer myself, I wince at the thought of more aggressive techniques such as direct intralesional injection of cyclic AMP (in the absence of any evidence of possible benefit), and I suggest animal trials and possibly trials in normal volunteers before progression to further use on patients.It also seems possible that the use of scraping
Warren AE. Cyclic AMP for Psoriasis. JAMA. 1974;228(6):695. doi:10.1001/jama.1974.03230310017009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: